At Experimentica we dedicate a significant amount of state-of-the-art methods for defining broad array of ophthalmic indications.
Together with our partners from academia and industry we are participating in a number of extramurally funded research programs among others on diabetic retinopathy, development of artificial cornea and ocular surface diseases.
R&D project on a novel diabetic retinopathy model
The North Savo ELY Centre for Economic Development, Transport and the Environment, awarded Experimentica Ltd. funding supporting an expansion of laboratory animal center and a development of a novel model for diabetic retinopathy.
The funding granted is >200 000 € for the 2-year funding period (2017-2018).
Eurostars, an European funding programme has been approved an application for the development of a novel eye-drop drug for the preventive treatment of diabetic retinopathy under the project name “PREVIN” in consortium together with Experimentica Ltd., Medical University of Vienna, Nucro-Technics, University of Copenhagen and Zealand University Hospital.
The overall project budget covers a period of 36 months and amounts to EUR 2.1 million. Business Finland (formerly the Finnish Funding Agency for Technology and Innovation, Tekes) granted the Experimentica Ltd part of the R&D project over 150.000 €.
More details: https://www.eurostars-eureka.eu/project/id/11008
Young Innovative Company funding
Experimentica Ltd was selected to a Young Innovative Company (YIC) funding program, phase I, by Business Finland starting the beginning of 2018 to accelerate the global growth and to open up new markets in Asia, to development of business activities globally.
Business Finland provides funding for the most ambitious and rapidly growing innovative companies in Finland and currently there are only thirteen companies in the Life Sciences and Health professions supported by YIC funding.
Subscribe to Our Newsletter!
We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers to!